NN Investment Partners Holdings’s Sarepta Therapeutics SRPT Stock Holding History

NN Investment Partners Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,721	Closed	-$1.1M	–	873
2021 Q1	$1.1M	Buy	14,721 +2,563	+21%	+$237K	0.01%	642
2020 Q4	$2.07M	Buy	12,158 +3,625	+42%	+$537K	0.01%	514
2020 Q3	$1.2M	Sell	8,533 -675	-7%	-$103K	0.01%	572
2020 Q2	$1.48M	Buy	+9,208	New	+$1.25M	0.01%	552

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NN Investment Partners Holdings's SRPT Position: Q2 2021 in Review

NN Investment Partners Holdings sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 14,721 shares — an estimated $1.1M sold.

NN Investment Partners Holdings first reported a position in SRPT in Q2 2020 and held it in 4 quarters. The position peaked at $2.07M in Q4 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

NN Investment Partners Holdings reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
NN Investment Partners Holdings sold 14,721 Sarepta Therapeutics shares in Q2 2021, an estimated $1.1M.
NN Investment Partners Holdings first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 4 quarters.
NN Investment Partners Holdings's Sarepta Therapeutics position peaked at $2.07M in Q4 2020.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on NN Investment Partners Holdings's 13F filing for Q2 2021, filed 14 Jul 2021.